A retrospective multicenter study of fatal pediatric melanoma - 10/10/20
, Danna Moustafa, BS a, b, Diana Bartenstein, MD a, b, c, Meera Brahmbhatt, MD d, Kelly Cordoro, MD e, f, Laura Gardner, MD g, Abigail Gauthier, BS h, Douglas Grossman, MD, PhD g, i, Deepti Gupta, MD j, k, Raegan D. Hunt, MD, PhD l, m, Melinda Jen, MD n, o, Pei-Chi Kao, MPH a, c, p, Lacey L. Kruse, MD q, r, Leslie P. Lawley, MD d, Wendy B. London, PhD a, c, p, Danny Mansour, MD s, t, Judith A. O'Haver, PhD, RN u, Thuy Phung, MD, PhD l, m, Elena Pope, MD, MSc s, t, Harper N. Price, MD u, Tova Rogers, MD v, Sonal D. Shah, MD e, f, Zachary Wolner, MD v, Jennifer Huang, MD a, c, Ashfaq A. Marghoob, MD vAbstract |
Background |
Pediatric melanoma is rare and diagnostically challenging.
Objective |
To characterize clinical and histopathologic features of fatal pediatric melanomas.
Methods |
Multicenter retrospective study of fatal melanoma cases in patients younger than 20 years diagnosed between 1994 and 2017.
Results |
Of 38 cases of fatal pediatric melanoma identified, 57% presented in white patients and 19% in Hispanic patients. The average age at diagnosis was 12.7 years (range, 0.0-19.9 y), and the average age at death was 15.6 years (range, 1.2-26.2 y). Among cases with known identifiable subtypes, 50% were nodular (8/16), 31% were superficial spreading (5/16), and 19% were spitzoid melanoma (3/16). One fourth (10/38) of melanomas arose in association with congenital melanocytic nevi.
Limitations |
Retrospective nature, cohort size, and potential referral bias.
Conclusions |
Pediatric melanoma can be fatal in diverse clinical presentations, including a striking prevalence of Hispanic patients compared to adult disease, and with a range of clinical subtypes, although no fatal cases of spitzoid melanoma were diagnosed during childhood.
Le texte complet de cet article est disponible en PDF.Key words : melanoma, oncology, pediatric dermatology, pediatric melanoma
Abbreviations used : CMN, FISH, LVI, SD, SLNB
Plan
| Funding sources: Supported by a 2019 Pediatric Dermatology Research Alliance Study Support Grant and 2017 Society for Pediatric Dermatology Pediatric Dermatology Research Alliance Pilot Award. Dr Hawryluk is supported by the Dermatology Foundation and the Harvard Medical School Eleanor and Miles Shore Fellowship Award. |
|
| Conflicts of interest: None disclosed. |
|
| This work was previously presented at the 2019 Pediatric Dermatology Research Alliance Annual Meeting in Chicago, IL, November 15, 2019. |
|
| IRB approval status: Reviewed and approved by Dana-Farber Cancer Institute IRB 15-156 as the central IRB and also approved by the IRBs at all collaborating institutions per regulations at the time of study initiation. |
Vol 83 - N° 5
P. 1274-1281 - novembre 2020 Retour au numéro
Article précédent
- Atypical postradiation vascular proliferation: Coping with uncertainty
- Warren R. Heymann
- Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial
- Amy S. Paller, Elaine C. Siegfried, Diamant Thaçi, Andreas Wollenberg, Michael J. Cork, Peter D. Arkwright, Melinda Gooderham, Lisa A. Beck, Mark Boguniewicz, Lawrence Sher, Jamie Weisman, John T. O'Malley, Naimish Patel, Megan Hardin, Neil M.H. Graham, Marcella Ruddy, Xian Sun, John D. Davis, Mohamed A. Kamal, Faisal A. Khokhar, David M. Weinreich, George D. Yancopoulos, Bethany Beazley, Ashish Bansal, Brad Shumel
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?